ARTICLE | Company News
FDA restricts Keytruda, Tecentriq monotherapy
June 21, 2018 10:07 PM UTC
FDA restricted the labels of Keytruda pembrolizumab and Tecentriq atezolizumab as monotherapy for urothelial cancer in a first-line setting.
The update applies to Keytruda or Tecentriq's use in locally advanced or metastatic urothelial carcinoma to patients ineligible for cisplatin-containing therapy who have PD-L1-expressing tumors, and to patients ineligible for platinum-containing chemotherapy regardless of PD-L1 status. ...